Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,091.98 USD
-53.05 (-4.63%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1,090.95 -1.03 (-0.09%) 7:10 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 81 - 100 ( 596 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 7122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Immunology Investor Event Highlights Dupixent Successes; COPD Readout in 2023; Making Inroads into China and More
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Rival List Narrows; Wet AMD Contender, KSI-301 Fails in a Phase 2b/3 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Trial For Omalizumab Refractory CSU Stopped Due to Futility
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M